| pubmed-article:8609093 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:8609093 | lifeskim:mentions | umls-concept:C1123023 | lld:lifeskim |
| pubmed-article:8609093 | lifeskim:mentions | umls-concept:C0018823 | lld:lifeskim |
| pubmed-article:8609093 | lifeskim:mentions | umls-concept:C0039195 | lld:lifeskim |
| pubmed-article:8609093 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
| pubmed-article:8609093 | lifeskim:mentions | umls-concept:C1999216 | lld:lifeskim |
| pubmed-article:8609093 | lifeskim:mentions | umls-concept:C0387387 | lld:lifeskim |
| pubmed-article:8609093 | lifeskim:mentions | umls-concept:C0591833 | lld:lifeskim |
| pubmed-article:8609093 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:8609093 | pubmed:dateCreated | 1996-5-28 | lld:pubmed |
| pubmed-article:8609093 | pubmed:abstractText | Metacycloprodigiosin is an antibiotic that has been shown to suppress T-cell proliferation induced by concanavalin A in vitro. We examined the effect of metacycloprodigiosin on murine allogenic skin and heart transplantation models, and compared graft rejection with donor-specific cytotoxic T-cells and antibody activity. The antibiotic slightly prolonged the survival of C57Bl/6 heart and skin grafts in BALB/c mice, although the effect was less that that of cyclosporin A. The effect was more evident in Bm1 (H-2D mutant) skin grafts on C57B1/6 hosts or in a minor histocompatibility antigen-mismatched model. In contrast, metacycloprodigiosin suppressed anti-graft cytotoxic T-cell activity of BALB/c spleen grafted with C57B1/6 skin as comparable to cyclosporin A, but had only partial effect on antibody production. Thus, metacycloprodigiosin is more effective in reducing splenic cytotoxic T-cell activity than in prolonging murine skin or cardiac allografts. | lld:pubmed |
| pubmed-article:8609093 | pubmed:language | eng | lld:pubmed |
| pubmed-article:8609093 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8609093 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:8609093 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8609093 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8609093 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8609093 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:8609093 | pubmed:month | Jan | lld:pubmed |
| pubmed-article:8609093 | pubmed:issn | 0021-8820 | lld:pubmed |
| pubmed-article:8609093 | pubmed:author | pubmed-author:ShearerG MGM | lld:pubmed |
| pubmed-article:8609093 | pubmed:author | pubmed-author:NagaiKK | lld:pubmed |
| pubmed-article:8609093 | pubmed:author | pubmed-author:MillerM WMW | lld:pubmed |
| pubmed-article:8609093 | pubmed:author | pubmed-author:MagaeJJ | lld:pubmed |
| pubmed-article:8609093 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:8609093 | pubmed:volume | 49 | lld:pubmed |
| pubmed-article:8609093 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:8609093 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:8609093 | pubmed:pagination | 86-90 | lld:pubmed |
| pubmed-article:8609093 | pubmed:dateRevised | 2003-11-14 | lld:pubmed |
| pubmed-article:8609093 | pubmed:meshHeading | pubmed-meshheading:8609093-... | lld:pubmed |
| pubmed-article:8609093 | pubmed:meshHeading | pubmed-meshheading:8609093-... | lld:pubmed |
| pubmed-article:8609093 | pubmed:meshHeading | pubmed-meshheading:8609093-... | lld:pubmed |
| pubmed-article:8609093 | pubmed:meshHeading | pubmed-meshheading:8609093-... | lld:pubmed |
| pubmed-article:8609093 | pubmed:meshHeading | pubmed-meshheading:8609093-... | lld:pubmed |
| pubmed-article:8609093 | pubmed:meshHeading | pubmed-meshheading:8609093-... | lld:pubmed |
| pubmed-article:8609093 | pubmed:meshHeading | pubmed-meshheading:8609093-... | lld:pubmed |
| pubmed-article:8609093 | pubmed:meshHeading | pubmed-meshheading:8609093-... | lld:pubmed |
| pubmed-article:8609093 | pubmed:meshHeading | pubmed-meshheading:8609093-... | lld:pubmed |
| pubmed-article:8609093 | pubmed:meshHeading | pubmed-meshheading:8609093-... | lld:pubmed |
| pubmed-article:8609093 | pubmed:meshHeading | pubmed-meshheading:8609093-... | lld:pubmed |
| pubmed-article:8609093 | pubmed:meshHeading | pubmed-meshheading:8609093-... | lld:pubmed |
| pubmed-article:8609093 | pubmed:year | 1996 | lld:pubmed |
| pubmed-article:8609093 | pubmed:articleTitle | Effect of metacycloprodigiosin, an inhibitor of killer T cells on murine skin and heart transplants. | lld:pubmed |
| pubmed-article:8609093 | pubmed:affiliation | Experimental Immunology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA. | lld:pubmed |
| pubmed-article:8609093 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8609093 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8609093 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8609093 | lld:pubmed |
